Liquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024. In the quarter to June 2026, revenue grew 1,842.7%, EPS grew 271.4%, free cash flow grew 270.2% and total debt fell 9.04%, each against the same quarter a year earlier.
Follow LQDA
Liquidia Corporation (LQDA) P/E ratio
As of 16 October 2026, Liquidia Corporation (LQDA) trades at a P/E ratio of 21.9×. Over the past ten years it has ranged from 0.0× (March 2026) to 326× (June 2026); the current reading is higher than 94% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 19.2× and in line with the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 50.8× | (67.71%) |
| Mar 2026 | 157× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRGO Perrigo Company plc compare | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. compare | n/m |
| ALVO Alvotech compare | n/m |
| AMLX Amylyx Pharmaceuticals, Inc. compare | n/m |
| SUPN Supernus Pharmaceuticals, Inc. compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| INDV Indivior Pharmaceuticals Inc. compare | 11.2× |
| PBH Prestige Consumer Healthcare Inc. compare | 13.9× |
| LQDA Liquidia Corporation | 21.9× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)